Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Pediatric-plan strategist must settle whether to drop a secondary endpoint that will dominate the AdCom because a CMO 483 that maps to the NDA CMC module hit a biologics company planning a biosimilar pathway. The evidence on hand is biosimilar analytical similarity report; name the Pharma & Life Sciences option that file actually supports.

DECISION Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after a CMO 483 that maps to the NDA CMC module. 2. Keep Pause the pathway in force until biosimilar analytical similarity report is completed after a CMO 483 that maps to the NDA CMC module for pediatric-plan strategist. 3. Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision to drop a secondary turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for pediatric-plan strategist - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Pharmacovigilance finding in biosimilar analytical similarity report that a second reviewer can re-perform - Missing page in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module, if any